- Home
- HERZ vs ITRM Comparison
HERZ vs ITRM Comparison
Compare HERZ & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HERZ | ITRM |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 24.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | HERZ | ITRM |
|---|---|---|
| Price | $18.14 | $0.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 5.3K | ★ 30.9M |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.62 | $0.03 |
| 52 Week High | $19.30 | $1.16 |
Technical Indicators
Market Signals| Indicator | HERZ | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 26.10 |
| Support Level | $13.85 | N/A |
| Resistance Level | $19.30 | $0.39 |
| Average True Range (ATR) | 0.86 | 0.02 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 74.82 | 3.34 |
Price Performance
Historical ComparisonAbout HERZ Herzfeld Credit Income Fund Inc.
Herzfeld Credit Income Fund Inc is a non-diversified, closed-end management investment company. Its primary investment objective is to maximize risk-adjusted total returns, and its secondary investment objective is to generate high current income.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.